Nexvet – Two industry leaders join the Board of Directors

DUBLIN, Ireland, MELBOURNE, Australia–‐ September 18, 2014. Link here. Veterinary biologic therapy developer Nexvet Biopharma today announced the appointments of Dr. Ashraf Hanna, M.D., Ph.D., and Dr. Joseph McCracken D.V.M., M.S., to its Board of Directors. Dr. Hanna is the Vice President of Commercial and Medical Affairs Finance at Genentech and Chief Financial Officer for the […]

Nexvet expands veterinary biologics research team

15 September 2014. Posted in Pharma & Biopharma on 15 September, 2014. Nexvet Biopharma has added two former CSL (ASX:CSL) scientists to its veterinary biologics research team. CSL’s former director of preclinical cell biology, Dr Samantha Busfield, and former director of analytical biochemistry, Dr Dallas Hartman, have both joined Nexvet’s veterinary biologics research centre in Melbourne. The centre is designed […]

SeaDragon 2014 Annual Meeting Results and Determinations

19 August 2014. Link here. The following resolutions were put to shareholders of SeaDragon Limited at its Annual Meeting held yesterday: 1. That Dr. Doug Wilson, retiring from office as Director of SeaDragon Limited by rotation, is re-elected as a Director of SeaDragon Limited; 2. That Mr. Jeremy Curnock Cook, retiring from office as Director of SeaDragon […]

Rex Bionics awarded major research & development grant by NZ Government

11 August 2014. Link here. Rex Bionics Plc (AIM: RXB), the developer and manufacturer of hands-free robotic exoskeletons for use by wheelchair users, today announces that its Auckland-based subsidiary Rex Bionics Ltd (RBL) has been awarded substantial new grant funding by the New Zealand Government to support the research and development of REX 3, the platform […]

SeaDragon Update: Edison Investment Research Releases SeaDragon Update

NZX – market Information 7 August 2014. Link here. Edison Investment Research Releases SeaDragon Update Edison Investment Research has released a SeaDragon Corporate outlook that can be found attached to this release and also available on our website. Contact Ross Keeley SeaDragon Chief Executive Officer Telephone: 03 547 0336 About SeaDragon: www.seadragon.co.nz SeaDragon (NZX:SEA) is Australasia’s […]

Rex Bionics: Interim Results for six months ended 31 May 2014

5 August 2014. Link here. Rex Bionics Plc (“Rex Bionics” or the “Company”) Maiden Interim Results for the six months ended 31 May 2014 5 August 2014, Rex Bionics Plc (RXB) (formerly Union MedTech Plc) the AIM-listed developer and manufacturer of hands-free robotic exoskeletons for use by wheelchair users, today announces its maiden unaudited results for […]

Rex Bionics: Appointment of Crispin Simon as CEO

Released 5 August 2014. Link here. Rex Bionics Plc (“Rex Bionics” or the “Company”) Appointment of Crispin Simon as Chief Executive Officer Rex Bionics Plc (AIM: RXB), the developer and manufacturer of hands-free robotic exoskeletons for use by wheelchair users, today announces the appointment of Crispin Simon as Chief Executive Officer. Crispin, who has a 25-year […]

SeaDragon Appoints Independent Director – Patrick Geals

Link here. 28 July 2014. SeaDragon Limited appoints Patrick Geals as a Non-Executive Independent Director SeaDragon Limited (SeaDragon), Australasia’s largest refiner and blender of high-quality internationally certified concentrated fish oils and fractions has appointed pharmaceutical and food industry expert Patrick Geals as a Non-Executive Independent Director. Welcoming Mr. Geals to the board, SeaDragon Chairman Dr. Doug […]

Nexus6’s Smartinhaler Dramatically Improves Medication Adherence

Link here. July 23rd, 2014. Results published today in the prestigious Journal of Allergy and Clinical Immunology (JACI) announce a ground-breaking increase in adherence with asthma medications for patients provided with a novel device called the Smartinhaler, manufactured by digital health company Nexus6 Ltd. The research was conducted by the highly regarded Woolcock Institute of Medical Research […]

REX to exhibit at the Hamlyn Symposium on Medical Robots

Released : 10 July 2014 RNS Number : 8968L Link here.   REX to exhibit at the Hamlyn Symposium on Medical Robots Rex Bionics plc (AIM: RXB), the developer and manufacturer of REX products: hands-free robotic exoskeletons for use by wheelchair users, announces that it will be exhibiting at the 7th Hamlyn Symposium on Medical Robots, at the […]